Acadia Pharmaceuticals Inc (ACAD)

Precedente Chiudi:

$17.08

Aprire:

$17.44

Volume 24 ore:

1.15M

Capitalizzazione di mercato:

$2.82B

Reddito:

$726.44M

Utile/perdita netta:

$-61.29M

Rapporto P/E:

-18.53

EPS:

-0.92

Flusso di cassa netto:

$-23.35M

1 W Prestazione:

+2.03%

1M Prestazione:

-7.44%

6M Prestazione:

-29.16%

1 anno Prestazione:

-19.58%

Intervallo 1D:

$17.03

$17.58

Portata 52W:

$16.16

$33.99

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Nome

Acadia Pharmaceuticals Inc

Settore

Healthcare (1213)

Industria

Biotechnology (699)

Telefono

858-558-2871

Indirizzo

3611 Valley Centre Drive, Suite 300, San Diego

Dipendente

410

Cinguettio

@acadiapharma

Prossima data di guadagno

2024-05-08

Ultimi documenti SEC

ACAD's Discussions on Twitter

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-01-30	Iniziato	Robert W. Baird	Outperform
2024-01-24	Aggiornamento	Needham	Hold → Buy
2023-12-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Downgrade	Deutsche Bank	Buy → Hold
2023-12-13	Iniziato	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-06	Aggiornamento	Mizuho	Neutral → Buy
2023-10-17	Iniziato	UBS	Buy
2023-10-10	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-11-04	Downgrade	Goldman	Neutral → Sell
2022-11-01	Iniziato	Loop Capital	Hold
2022-08-08	Downgrade	Citigroup	Buy → Neutral
2022-08-05	Downgrade	Citigroup	Buy → Neutral
2022-06-21	Downgrade	Jefferies	Buy → Underperform
2022-06-16	Aggiornamento	Jefferies	Hold → Buy
2022-03-16	Aggiornamento	Canaccord Genuity	Hold → Buy
2022-02-09	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-01-05	Aggiornamento	Citigroup	Neutral → Buy
2021-12-21	Downgrade	Guggenheim	Buy → Neutral
2021-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-06-10	Iniziato	Berenberg	Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-04-06	Downgrade	Goldman	Buy → Neutral
2021-04-06	Downgrade	Jefferies	Buy → Hold
2021-04-06	Downgrade	Mizuho	Buy → Neutral
2021-04-05	Downgrade	Raymond James	Outperform → Mkt Perform
2021-03-10	Downgrade	BofA Securities	Buy → Neutral
2021-03-09	Downgrade	Citigroup	Buy → Neutral
2021-03-09	Downgrade	Guggenheim	Buy → Neutral
2021-03-09	Reiterato	H.C. Wainwright	Buy
2021-03-09	Downgrade	Raymond James	Strong Buy → Outperform
2021-03-09	Downgrade	Stifel	Buy → Hold
2020-12-16	Iniziato	Mizuho	Buy
2020-11-16	Aggiornamento	Raymond James	Outperform → Strong Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Iniziato	Morgan Stanley	Overweight
2020-07-07	Aggiornamento	Stifel	Hold → Buy
2020-04-16	Iniziato	Jefferies	Buy
2020-03-31	Aggiornamento	Goldman	Neutral → Buy
2020-03-06	Iniziato	Citigroup	Buy
2019-12-16	Iniziato	Guggenheim	Buy
2019-10-24	Iniziato	Oppenheimer	Perform
2019-10-01	Iniziato	RBC Capital Mkts	Outperform
2019-09-13	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Aggiornamento	Canaccord Genuity	Hold → Buy
2019-07-23	Reiterato	Needham	Buy
2018-12-10	Iniziato	Canaccord Genuity	Hold
2018-09-21	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-08-09	Reiterato	Stifel	Hold
2018-08-07	Iniziato	Stifel	Hold
2018-08-06	Downgrade	Piper Jaffray	Overweight → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)

Benzinga

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals

Benzinga

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

Zacks Investment Research

Expert Ratings For ACADIA Pharmaceuticals

Benzinga

Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari

Acadia Pharmaceuticals Inc (ACAD) Reddito 2024

Acadia Pharmaceuticals Inc (ACAD) Reddito netto 2024

Acadia Pharmaceuticals Inc (ACAD) Flusso di cassa 2024

Acadia Pharmaceuticals Inc (ACAD) Utile per azione 2024

Acadia Pharmaceuticals Inc Azioni (ACAD) insider trading